|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Perlikos F, Harrington KJ and Syrigos KN:
Key molecular mechanisms in lung cancer invasion and metastasis: A
comprehensive review. Crit Rev Oncol Hematol. 87:1–11. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Howlader N, Forjaz G, Mooradian MJ, Meza
R, Kong CY, Cronin KA, Mariotto AB, Lowy DR and Feuer EJ: The
Effect of Advances in Lung-Cancer Treatment on Population
Mortality. N Engl J Med. 383:640–649. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Seyfried TN and Huysentruyt LC: On the
origin of cancer metastasis. Crit Rev Oncog. 18:43–73. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Santos JMO, Peixoto da Silva S, Costa NR,
Gil da Costa RM and Medeiros R: The role of MicroRNAs in the
metastatic process of high-risk HPV-induced cancers. Cancers
(Basel). 10:4932018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Woodhouse EC, Chuaqui RF and Liotta LA:
General mechanisms of metastasis. Cancer 80 (8 Suppl). S1529–S1537.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cheung KJ and Ewald AJ: A collective route
to metastasis: Seeding by tumor cell clusters. Science.
352:167–169. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gerlinger M, Horswell S, Larkin J, Rowan
AJ, Salm MP, Varela I, Fisher R, McGranahan N, Matthews N, Santos
CR, et al: Genomic architecture and evolution of clear cell renal
cell carcinomas defined by multiregion sequencing. Nat Genet.
46:225–233. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Noorani A, Li X, Goddard M, Crawte J,
Alexandrov LB, Secrier M, Eldridge MD, Bower L, Weaver J,
Lao-Sirieix P, et al: Genomic evidence supports a clonal diaspora
model for metastases of esophageal adenocarcinoma. Nat Genet.
52:74–83. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ruvkun G: Clarifications on miRNA and
cancer. Science. 311:36–37. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Stahlhut C and Slack FJ: MicroRNAs and the
cancer phenotype: Profiling, signatures and clinical implications.
Genome Med. 5:1112013. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Choudhury Y, Tay FC, Lam DH, Sandanaraj E,
Tang C, Ang BT and Wang S: Attenuated adenosine-to-inosine editing
of microRNA-376a* promotes invasiveness of glioblastoma cells. J
Clin Invest. 122:4059–4076. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Whiteside TL: Tumor-derived exosomes and
their role in cancer progression. Adv Clin Chem. 74:103–141. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ocansey DKW, Zhang L, Wang Y, Yan Y, Qian
H, Zhang X, Xu W and Mao F: Exosome-mediated effects and
applications in inflammatory bowel disease. Biol Rev Camb Philos
Soc. 95:1287–1307. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Perez-Hernandez J, Olivares D, Forner MJ,
Ortega A, Solaz E, Martinez F, Chaves FJ, Redon J and Cortes R:
Urinary exosome miR-146a is a potential marker of albuminuria in
essential hypertension. J Transl Med. 16:2282018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang X, Xin G and Sun D: Serum exosomal
miR-328, miR-575, miR-134 and miR-671-5p as potential biomarkers
for the diagnosis of Kawasaki disease and the prediction of
therapeutic outcomes of intravenous immunoglobulin therapy. Exp
Ther Med. 16:2420–2432. 2018.PubMed/NCBI
|
|
18
|
Kim JE, Eom JS, Kim WY, Jo EJ, Mok J, Lee
K, Kim KU, Park HK, Lee MK and Kim MH: Diagnostic value of
microRNAs derived from exosomes in bronchoalveolar lavage fluid of
early-stage lung adenocarcinoma: A pilot study. Thorac Cancer.
9:911–915. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Vanni I, Alama A, Grossi F, Dal Bello MG
and Coco S: Exosomes: A new horizon in lung cancer. Drug Discov
Today. 22:927–936. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hessvik NP and Llorente A: Current
knowledge on exosome biogenesis and release. Cell Mol Life Sci.
75:193–208. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kalluri R and LeBleu VS: The biology,
function, and biomedical applications of exosomes. Science.
367:eaau69772020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lee RC, Feinbaum RL and Ambros V: The C.
elegans heterochronic gene lin-4 encodes small RNAs with antisense
complementarity to lin-14. Cell. 75:843–854. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lee Y, Kim M, Han J, Yeom KH, Lee S, Baek
SH and Kim VN: MicroRNA genes are transcribed by RNA polymerase II.
EMBO J. 23:4051–4060. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Denli AM, Tops BB, Plasterk RH, Ketting RF
and Hannon GJ: Processing of primary microRNAs by the
Microprocessor complex. Nature. 432:231–235. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wilson RC, Tambe A, Kidwell MA, Noland CL,
Schneider CP and Doudna JA: Dicer-TRBP complex formation ensures
accurate mammalian microRNA biogenesis. Mol Cell. 57:397–407. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gregory RI, Chendrimada TP, Cooch N and
Shiekhattar R: Human RISC couples microRNA biogenesis and
posttranscriptional gene silencing. Cell. 123:631–640. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Thomson DW, Bracken CP and Goodall GJ:
Experimental strategies for microRNA target identification. Nucleic
Acids Res. 39:6845–6853. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bang C and Thum T: Exosomes: New players
in cell-cell communication. Int J Biochem Cell Biol. 44:2060–2064.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wittmann J and Jäck HM: Serum microRNAs as
powerful cancer biomarkers. Biochim Biophys Acta. 1806:200–207.
2010.PubMed/NCBI
|
|
31
|
Peinado H, Alečković M, Lavotshkin S,
Matei I, Costa-Silva B, Moreno-Bueno G, Hergueta-Redondo M,
Williams C, García-Santos G, Ghajar C, et al: Melanoma exosomes
educate bone marrow progenitor cells toward a pro-metastatic
phenotype through MET. Nat Med. 18:883–891. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mao L, Li X, Gong S, Yuan H, Jiang Y,
Huang W, Sun X and Dang X: Serum exosomes contain ECRG4 mRNA that
suppresses tumor growth via inhibition of genes involved in
inflammation, cell proliferation, and angiogenesis. Cancer Gene
Ther. 25:248–259. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mittal V: Epithelial mesenchymal
transition in tumor metastasis. Annu Rev Pathol. 13:395–412. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Morel AP, Lièvre M, Thomas C, Hinkal G,
Ansieau S and Puisieux A: Generation of breast cancer stem cells
through epithelial-mesenchymal transition. PLoS One. 3:e28882008.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Peinado H, Olmeda D and Cano A: Snail, Zeb
and bHLH factors in tumour progression: An alliance against the
epithelial phenotype? Nat Rev Cancer. 7:415–428. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
De Craene B and Berx G: Regulatory
networks defining EMT during cancer initiation and progression. Nat
Rev Cancer. 13:97–110. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kim H, Lee S, Shin E, Seong KM, Jin YW,
Youn H and Youn B: The emerging roles of exosomes as EMT regulators
in cancer. Cells. 9:8612020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Jin W: Role of JAK/STAT3 signaling in the
regulation of metastasis, the transition of cancer stem cells, and
chemoresistance of cancer by epithelial-mesenchymal transition.
Cells. 9:2172020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Xia Y, Wei K, Hu LQ, Zhou CR, Lu ZB, Zhan
GS, Pan XL, Pan CF, Wang J, Wen W, et al: Exosome-mediated transfer
of miR-1260b promotes cell invasion through Wnt/β-catenin signaling
pathway in lung adenocarcinoma. J Cell Physiol. 235:6843–6853.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chen X, Meng J, Yue W, Yu J, Yang J, Yao Z
and Zhang L: Fibulin-3 suppresses Wnt/β-catenin signaling and lung
cancer invasion. Carcinogenesis. 35:1707–1716. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wu H, Zhou J, Mei S, Wu D, Mu Z, Chen B,
Xie Y, Ye Y and Liu J: Circulating exosomal microRNA-96 promotes
cell proliferation, migration and drug resistance by targeting
LMO7. J Cell Mol Med. 21:1228–1236. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhang X, Sai B, Wang F, Wang L, Wang Y,
Zheng L, Li G, Tang J and Xiang J: Hypoxic BMSC-derived exosomal
miRNAs promote metastasis of lung cancer cells via STAT3-induced
EMT. Mol Cancer. 18:402019. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wang L, He J, Hu H, Tu L, Sun Z, Liu Y and
Luo F: Lung CSC-derived exosomal miR-210-3p contributes to a
pro-metastatic phenotype in lung cancer by targeting FGFRL1. J Cell
Mol Med. 24:6324–6339. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Tang YT, Huang YY, Li JH, Qin SH, Xu Y, An
TX, Liu CC, Wang Q and Zheng L: Alterations in exosomal miRNA
profile upon epithelial-mesenchymal transition in human lung cancer
cell lines. BMC Genomics. 19:8022018. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Holmgren L, O'Reilly MS and Folkman J:
Dormancy of micrometastases: Balanced proliferation and apoptosis
in the presence of angiogenesis suppression. Nat Med. 1:149–153.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Parangi S, O'Reilly M, Christofori G,
Holmgren L, Grosfeld J, Folkman J and Hanahan D: Antiangiogenic
therapy of transgenic mice impairs de novo tumor growth. Proc Natl
Acad Sci USA. 93:2002–2007. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Folkman J: Tumor angiogenesis: Therapeutic
implications. N Engl J Med. 285:1182–1186. 1971. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Masoud GN and Li W: HIF-1α pathway: Role,
regulation and intervention for cancer therapy. Acta Pharm Sin B.
5:378–389. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Hsu YL, Hung JY, Chang WA, Lin YS, Pan YC,
Tsai PH, Wu CY and Kuo PL: Hypoxic lung cancer-secreted exosomal
miR-23a increased angiogenesis and vascular permeability by
targeting prolyl hydroxylase and tight junction protein ZO-1.
Oncogene. 36:4929–4942. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Semenza GL: HIF-1 and human disease: One
highly involved factor. Genes Dev. 14:1983–1991. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Saponaro C, Malfettone A, Ranieri G, Danza
K, Simone G, Paradiso A and Mangia A: VEGF, HIF-1α expression and
MVD as an angiogenic network in familial breast cancer. PLoS One.
8:e530702013. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Edelbauer M, Datta D, Vos IH, Basu A,
Stack MP, Reinders ME, Sho M, Calzadilla K, Ganz P and Briscoe DM:
Effect of vascular endothelial growth factor and its receptor KDR
on the transendothelial migration and local trafficking of human T
cells in vitro and in vivo. Blood. 116:1980–1989. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Raza SL and Cornelius LA: Matrix
Metalloproteinases: Pro- and anti-angiogenic activities. J Investig
Dermatol Symp Proc. 5:47–54. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Mao S, Lu Z, Zheng S, Zhang H, Zhang G,
Wang F, Huang J, Lei Y, Wang X, Liu C, et al: Exosomal miR-141
promotes tumor angiogenesis via KLF12 in small cell lung cancer. J
Exp Clin Cancer Res. 39:1932020. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Liu Y, Luo F, Wang B, Li H, Xu Y, Liu X,
Shi L, Lu X, Xu W, Lu L, et al: STAT3-regulated exosomal miR-21
promotes angiogenesis and is involved in neoplastic processes of
transformed human bronchial epithelial cells. Cancer Lett.
370:125–135. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Grimolizzi F, Monaco F, Leoni F, Bracci M,
Staffolani S, Bersaglieri C, Gaetani S, Valentino M, Amati M,
Rubini C, et al: Exosomal miR-126 as a circulating biomarker in
non-small-cell lung cancer regulating cancer progression. Sci Rep.
7:152772017. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Olumi AF, Grossfeld GD, Hayward SW,
Carroll PR, Tlsty TD and Cunha GR: Carcinoma-associated fibroblasts
direct tumor progression of initiated human prostatic epithelium.
Cancer Res. 59:5002–5011. 1999.PubMed/NCBI
|
|
58
|
Fan J, Xu G, Chang Z, Zhu L and Yao J:
miR-210 transferred by lung cancer cell-derived exosomes may act as
proangiogenic factor in cancer-associated fibroblasts by modulating
JAK2/STAT3 pathway. Clin Sci (Lond). 134:807–825. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Qi Z, Yang DY and Cao J: Increased
micro-RNA 17, 21, and 192 gene expressions improve early diagnosis
in non-small cell lung cancer. Med Oncol. 31:1952014. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Tian X, Shen H, Li Z, Wang T and Wang S:
Tumor-derived exosomes, myeloid-derived suppressor cells, and tumor
microenvironment. J Hematol Oncol. 12:842019. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Whiteside TL: Exosomes and tumor-mediated
immune suppression. J Clin Invest. 126:1216–1223. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Yin Y, Cai X, Chen X, Liang H, Zhang Y, Li
J, Wang Z, Chen X, Zhang W, Yokoyama S, et al: Tumor-secreted
miR-214 induces regulatory T cells: A major link between immune
evasion and tumor growth. Cell Res. 24:1164–1180. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Fabbri M, Paone A, Calore F, Galli R,
Gaudio E, Santhanam R, Lovat F, Fadda P, Mao C, Nuovo GJ, et al:
MicroRNAs bind to Toll-like receptors to induce prometastatic
inflammatory response. Proc Natl Acad Sci USA. 109:E2110–E2116.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Adi Harel S, Bossel Ben-Moshe N, Aylon Y,
Bublik DR, Moskovits N, Toperoff G, Azaiza D, Biagoni F, Fuchs G,
Wilder S, et al: Reactivation of epigenetically silenced miR-512
and miR-373 sensitizes lung cancer cells to cisplatin and restricts
tumor growth. Cell Death Differ. 22:1328–1340. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Tang Y, Cui Y, Li Z, Jiao Z, Zhang Y, He
Y, Chen G, Zhou Q, Wang W, Zhou X, et al: Radiation-induced
miR-208a increases the proliferation and radioresistance by
targeting p21 in human lung cancer cells. J Exp Clin Cancer Res.
35:72016. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Tan Z, Xue H, Sun Y, Zhang C, Song Y and
Qi Y: The role of tumor inflammatory microenvironment in lung
cancer. Front Pharmacol. 12:6886252021. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Puig-Saus C, Gros A, Alemany R and
Cascalló M: Adenovirus i-leader truncation bioselected against
cancer-associated fibroblasts to overcome tumor stromal barriers.
Mol Ther. 20:54–62. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Crawford Y, Kasman I, Yu L, Zhong C, Wu X,
Modrusan Z, Kaminker J and Ferrara N: PDGF-C mediates the
angiogenic and tumorigenic properties of fibroblasts associated
with tumors refractory to anti-VEGF treatment. Cancer Cell.
15:21–34. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Chen LT, Xu SD, Xu H, Zhang JF, Ning JF
and Wang SF: MicroRNA-378 is associated with non-small cell lung
cancer brain metastasis by promoting cell migration, invasion and
tumor angiogenesis. Med Oncol. 29:1673–1680. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Sun S, Chen H, Xu C, Zhang Y, Zhang Q,
Chen L, Ding Q and Deng Z: Exosomal miR-106b serves as a novel
marker for lung cancer and promotes cancer metastasis via targeting
PTEN. Life Sci. 244:1172972020. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Xu X, Zhu S, Tao Z and Ye S: High
circulating miR-18a, miR-20a, and miR-92a expression correlates
with poor prognosis in patients with non-small cell lung cancer.
Cancer Med. 7:21–31. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Kottorou A, Dimitrakopoulos FI and Tsezou
A: Non-coding RNAs in cancer-associated cachexia: Clinical
implications and future perspectives. Transl Oncol. 14:1011012021.
View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Yao P, Potdar AA, Arif A, Ray PS,
Mukhopadhyay R, Willard B, Xu Y, Yan J, Saidel GM and Fox PL:
Coding region polyadenylation generates a truncated tRNA synthetase
that counters translation repression. Cell. 149:88–100. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Freire PP, Fernandez GJ, Cury SS, de
Moraes D, Oliveira JS, de Oliveira G, Dal-Pai-Silva M, Dos Reis PP
and Carvalho RF: The pathway to cancer cachexia: MicroRNA-regulated
networks in muscle wasting based on integrative meta-analysis. Int
J Mol Sci. 20:19622019. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Gao P, Niu N, Wei T, Tozawa H, Chen X,
Zhang C, Zhang J, Wada Y, Kapron CM and Liu J: The roles of signal
transducer and activator of transcription factor 3 in tumor
angiogenesis. Oncotarget. 8:69139–69161. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Margolis LM and Rivas DA: Potential role
of MicroRNA in the anabolic capacity of skeletal muscle with aging.
Exerc Sport Sci Rev. 46:86–91. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Hou B, Xu S, Xu Y, Gao Q, Zhang C, Liu L,
Yang H, Jiang X and Che Y: Grb2 binds to PTEN and regulates its
nuclear translocation to maintain the genomic stability in DNA
damage response. Cell Death Dis. 10:5462019. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Carr RM, Enriquez-Hesles E, Olson RL,
Jatoi A, Doles J and Fernandez-Zapico ME: Epigenetics of
cancer-associated muscle catabolism. Epigenomics. 9:1259–1265.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Terasawa K, Shimizu K and Tsujimoto G:
Synthetic Pre-miRNA-Based shRNA as potent RNAi triggers. J Nucleic
Acids. 2011:1315792011. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
György B, Hung ME, Breakefield XO and
Leonard JN: Therapeutic applications of extracellular vesicles:
Clinical promise and open questions. Annu Rev Pharmacol Toxicol.
55:439–464. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Kalra H, Drummen GP and Mathivanan S:
Focus on extracellular vesicles: introducing the next small big
thing. Int J Mol Sci. 17:1702016. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Yan W and Jiang S: Immune cell-derived
exosomes in the cancer-immunity cycle. Trends Cancer. 6:506–517.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Fu W, Lei C, Liu S, Cui Y, Wang C, Qian K,
Li T, Shen Y, Fan X, Lin F, et al: CAR exosomes derived from
effector CAR-T cells have potent antitumour effects and low
toxicity. Nat Commun. 10:43552019. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
EL Andaloussi S, Mäger I, Breakefield XO
and Wood MJ: Extracellular vesicles: Biology and emerging
therapeutic opportunities. Nat Rev Drug Discov. 12:347–357. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Lai RC, Yeo RW, Tan KH and Lim SK:
Exosomes for drug delivery-a novel application for the mesenchymal
stem cell. Biotechnol Adv. 31:543–551. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Syn NL, Wang L, Chow EK, Lim CT and Goh
BC: Exosomes in cancer nanomedicine and immunotherapy: Prospects
and challenges. Trends Biotechnol. 35:665–676. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Wu P, Zhang B, Ocansey DKW, Xu W and Qian
H: Extracellular vesicles: A bright star of nanomedicine.
Biomaterials. 269:1204672021. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Nie H, Xie X, Zhang D, Zhou Y, Li B, Li F,
Li F, Cheng Y, Mei H, Meng H and Jia L: Use of lung-specific
exosomes for miRNA-126 delivery in non-small cell lung cancer.
Nanoscale. 12:877–887. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Johnsen KB, Gudbergsson JM, Skov MN,
Pilgaard L, Moos T and Duroux M: A comprehensive overview of
exosomes as drug delivery vehicles-endogenous nanocarriers for
targeted cancer therapy. Biochim Biophys Acta. 1846:75–87.
2014.PubMed/NCBI
|
|
90
|
Srivastava A, Amreddy N, Babu A,
Panneerselvam J, Mehta M, Muralidharan R, Chen A, Zhao YD, Razaq M,
Riedinger N, et al: Nanosomes carrying doxorubicin exhibit potent
anticancer activity against human lung cancer cells. Sci Rep.
6:385412016. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Cortez MA, Ivan C, Valdecanas D, Wang X,
Peltier HJ, Ye Y, Araujo L, Carbone DP, Shilo K, Giri DK, et al:
PDL1 regulation by p53 via miR-34. J Natl Cancer Inst.
108:djv3032015.PubMed/NCBI
|
|
92
|
Sun Z, Shi K, Yang S, Liu J, Zhou Q, Wang
G, Song J, Li Z, Zhang Z and Yuan W: Effect of exosomal miRNA on
cancer biology and clinical applications. Mol Cancer. 17:1472018.
View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Amiri A, Pourhanifeh MH, Mirzaei HR,
Nahand JS, Moghoofei M, Sahebnasagh R, Mirzaei H and Hamblin MR:
Exosomes and lung cancer: Roles in pathophysiology, diagnosis and
therapeutic applications. Curr Med Chem. 28:308–328. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Li Y, Yin Z, Fan J, Zhang S and Yang W:
The roles of exosomal miRNAs and lncRNAs in lung diseases. Signal
Transduct Target Ther. 4:472019. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Chen R, Xu X, Qian Z, Zhang C, Niu Y, Wang
Z, Sun J, Zhang X and Yu Y: The biological functions and clinical
applications of exosomes in lung cancer. Cell Mol Life Sci.
76:4613–4633. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Fortunato O, Gasparini P, Boeri M and
Sozzi G: Exo-miRNAs as a new tool for liquid biopsy in lung cancer.
Cancers (Basel). 11:8882019. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Sayeed N and Sugaya K: Exosome mediated
Tom40 delivery protects against hydrogen peroxide-induced oxidative
stress by regulating mitochondrial function. PLoS One.
17:e02725112022. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Rajput A, Varshney A, Bajaj R and
Pokharkar V: Exosomes as new generation vehicles for drug delivery:
Biomedical applications and future perspectives. Molecules.
27:72892022. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Kok VC and Yu CC: Cancer-derived exosomes:
Their role in cancer biology and biomarker development. Int J
Nanomedicine. 15:8019–8036. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Hou C, Wu Q, Xu L, Cui R, Ou R, Li D and
Xu Y: Exploiting the potential of extracellular vesicles as
delivery vehicles for the treatment of melanoma. Front Bioeng
Biotechnol. 10:10543242022. View Article : Google Scholar : PubMed/NCBI
|
